Qiagen N.V, Tokai deal

Qiagen and Tokai partnered to co-develop a liquid biopsy circulating tumor cells (CTCs) companion diagnostic. The diagnostic will be used with Tokai’s galeterone, a selective androgen receptor modulator (SARM) and cytochrome P450 17 alpha-hydroxylase/C17,20 lyase (CYP17) inhibitor. Galeterone is slated to begin Phase III trials to treat castration-resistant prostate cancer (CRPC) this half, with top-line data expected by the end of 2016. The partners will use the companion diagnostic to identify patients with androgen receptor splice variant 7 (AR- V7) to enroll in the trial. Qiagen is responsible for developing and commercializing the companion diagnostic. ...